营收增37%仍亏4.4亿:诺诚健华如何破解

金融界
28 Mar

2024年, 诺诚健华 交出了一份营收显著增长但尚未实现盈利的成绩单。年报显示,公司全年实现营业总收入10.09亿元,同比增长36.68%,归母净亏损4.41亿元,同比收窄30.20%。这份数据背后,核心产品奥布替尼的销售放量成为关键 驱动力 ,但研发投入持续高企、新药管线商业化进程缓慢等问题,仍让这家 创新药 企面临多重挑战。核心产品奥布替尼突破10亿收入,但产品线单一风险凸显作为国内首个获批...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10